Literature DB >> 8698504

Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

E R van der Voort1, P van der Ley, J van der Biezen, S George, O Tunnela, H van Dijken, B Kuipers, J Poolman.   

Abstract

A set of isogenic strains was constructed from the meningococcal reference strain H44/76 (B:15:P1.7,16) which differed only in their outer membrane protein (OMP) compositions. First, three isogenic strains lacking the expression of either class 3 (PorB) or class 4 (RmpM) OMP or both were obtained. Second, three isogenic class 1 OMP loop-deficient strains of H44/76 lacking the predicted loop 1 or 4 or both of class 1 OMP (PorA) were obtained. Third, three isogenic class 1 OMP strains which differed by point mutations in the predicted loop 4 of subtype P1.16 were constructed. Strains were constructed through transformation with gene constructs made in Escherichia coli and their homologous recombination into the meningococcal chromosome. This study describes the contribution of one of the six class 1 OMPs, PorA P1.7,16, in the development of bactericidal antibodies after a single immunization of adult volunteers with 50 or 100 micrograms of protein within a hexavalent PorA outer membrane vesicle vaccine. PorA-, PorB-, and RpmM-deficient isogenic strains were used to define the human immune response against PorA. The loop-deficient isogenic strains were used to define the contribution of loops 1 and 4 of PorA in the development of bactericidal anti-PorA antibodies. The isogenic strains carrying a point mutation in loop 4 were used to study the cross-reactivity of the induced bactericidal antibodies against target strains showing microheterogeneity. The results indicate that a single immunization with the hexavalent PorA vaccine induced a dose-dependent bactericidal immune response, which is directed mainly against PorA. The epitope specificity of antibodies is directed mostly against loop 1, although loop 4 and as-yet-unidentified epitopes of PorA P1.7,16 are also involved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698504      PMCID: PMC174135          DOI: 10.1128/iai.64.7.2745-2751.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues.

Authors:  J Finne; D Bitter-Suermann; C Goridis; U Finne
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

Review 2.  Chimeric single-stranded DNA phage-plasmid cloning vectors.

Authors:  D A Mead; B Kemper
Journal:  Biotechnology       Date:  1988

Review 3.  Vaccines for prevention of meningococcal disease.

Authors:  C E Frasch
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

4.  Sequence and properties of pIM13, a macrolide-lincosamide-streptogramin B resistance plasmid from Bacillus subtilis.

Authors:  M Monod; C Denoya; D Dubnau
Journal:  J Bacteriol       Date:  1986-07       Impact factor: 3.490

5.  Status of a group B Neisseria meningitidis vaccine.

Authors:  C E Frasch
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

6.  Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA.

Authors:  H Abdillahi; J T Poolman
Journal:  Microb Pathog       Date:  1988-01       Impact factor: 3.738

7.  Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis.

Authors:  R J Scholten; H A Bijlmer; J T Poolman; B Kuipers; D A Caugant; L Van Alphen; J Dankert; H A Valkenburg
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

8.  Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development.

Authors:  K Saukkonen; H Abdillahi; J T Poolman; M Leinonen
Journal:  Microb Pathog       Date:  1987-10       Impact factor: 3.738

Review 9.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  36 in total

1.  Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.

Authors:  E Rosenqvist; A Musacchio; A Aase; E A Høiby; E Namork; J Kolberg; E Wedege; A Delvig; R Dalseg; T E Michaelsen; J Tommassen
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

2.  Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.

Authors:  K T Mountzouros; A P Howell
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

3.  Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.

Authors:  Yanwen Li; Yao-hui Sun; Cathy Ison; Myron M Levine; Christoph M Tang
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

5.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

Review 6.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

7.  Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Authors:  Wendell D Zollinger; Elizabeth E Moran; Deborah H Schmiel
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

8.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

9.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

10.  Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Authors:  F Oftung; L M Naess; L M Wetzler; G E Korsvold; A Aase; E A Høiby; R Dalseg; J Holst; T E Michaelsen; B Haneberg
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.